BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aljebreen AM, Alharbi OR, Azzam NA, Almalki AS, Alswat KA, Almadi MA. Clinical epidemiology and phenotypic characteristics of Crohn's disease in the central region of Saudi Arabia. Saudi J Gastroenterol 2014;20:162-9. [PMID: 24976279 DOI: 10.4103/1319-3767.132993] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Alharbi O, Almadi MA, Azzam N, Aljebreen AM, AlAmeel T, Schreiber S, Mosli MH. Clinical characteristics, natural history, and outcomes of Crohn's-related intra-abdominal collections. Saudi J Gastroenterol 2021;27:79-84. [PMID: 33723092 DOI: 10.4103/sjg.SJG_89_20] [Reference Citation Analysis]
2 Adam H, Alqassas M, Saadah OI, Mosli M. Extraintestinal Manifestations of Inflammatory Bowel Disease in Middle Eastern Patients. J Epidemiol Glob Health 2020;10:298-303. [PMID: 32959603 DOI: 10.2991/jegh.k.200330.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Chin YH, Ng CH, Lin SY, Jain SR, Kong G, Koh JWH, Tan DJH, Ong DEH, Muthiah MD, Chong CS, Foo FJ, Leong R, Chan WPW. Systematic review with meta-analysis: The prevalence, risk factors and outcomes of upper gastrointestinal tract Crohn's disease. Dig Liver Dis 2021;53:1548-58. [PMID: 34412995 DOI: 10.1016/j.dld.2021.07.037] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Isa HM, Mohamed AM, Al-Jowder HE, Matrook KA, Althawadi HH. Pediatric Crohn's Disease in Bahrain. Oman Med J. 2018;33:299-308. [PMID: 30038729 DOI: 10.5001/omj.2018.56] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Al-Quorain AA. Extraintestinal Manifestations of Inflammatory Bowel Disease. Saudi J Med Med Sci 2019;7:65. [PMID: 31080384 DOI: 10.4103/sjmms.sjmms_111_19] [Reference Citation Analysis]
6 Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720-727. [PMID: 26323879 DOI: 10.1038/nrgastro.2015.150] [Cited by in Crossref: 766] [Cited by in F6Publishing: 707] [Article Influence: 109.4] [Reference Citation Analysis]
7 Algethmi W, Baumann C, Alnajjar W, Sroji A, Alsahafi M, Jawa H, Qari Y, Peyrin-Biroulet L, Saadah OI, Mosli M. Environmental exposures and the risk of inflammatory bowel disease: a case-control study from Saudi Arabia. Eur J Gastroenterol Hepatol 2020;32:358-64. [PMID: 31851095 DOI: 10.1097/MEG.0000000000001619] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mosli M, Alawadhi S, Hasan F, Abou Rached A, Sanai F, Danese S. Incidence, Prevalence, and Clinical Epidemiology of Inflammatory Bowel Disease in the Arab World: A Systematic Review and Meta-Analysis. Inflamm Intest Dis 2021;6:123-31. [PMID: 34722642 DOI: 10.1159/000518003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 AlAskar D, AlSardi M, Al Sulais E, Mosli M, AlAmeel T. Risk of neutropenia in inflammatory bowel disease patients treated with TNF inhibitors: A single-center, retrospective cohort study. Saudi J Gastroenterol 2020. [PMID: 32496224 DOI: 10.4103/sjg.SJG_41_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Alharbi R, Almahmudi F, Makhdoom Y, Mosli M. Knowledge and attitudes of primary healthcare physicians toward the diagnosis and management of inflammatory bowel disease following an educational intervention: A comparative analysis. Saudi J Gastroenterol 2019;25:277-85. [PMID: 31187783 DOI: 10.4103/sjg.SJG_169_19] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Subramanian S, Ekbom A, Rhodes JM. Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD? Gut 2017;66:362-81. [PMID: 27802156 DOI: 10.1136/gutjnl-2016-312673] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 8.2] [Reference Citation Analysis]
12 AlRuthia Y, Alharbi O, Aljebreen AM, Azzam NA, Almadi MA, Bahari OH, Almalki KA, Atham AT, Alanazi AS, Saeed M, HajkhderMullaissa B, Alsenaidy M, Balkhi B. Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia. Cost Eff Resour Alloc 2019;17:25. [PMID: 31827409 DOI: 10.1186/s12962-019-0194-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]